BenevolentAI Investor Presentation Deck
We expect BEN-2293 to provide both symptomatic relief
and to reverse disease progression in atopic dermatitis
● BEN-2293 is highly selective for Trk receptors, with IC50
potencies in the low nM range for TrkA, B, and C
● BEN-2293 dose dependently inhibits release of
inflammatory Th1 and Th2 cytokines TNFa, IFNY, IL-13, and
IL-4 in human peripheral blood mononuclear cells (PBMCs)
stimulated with an inflammatory T-cell stimulus (anti-
CD3/CD28)
● BEN-2293 inhibits the release of Calcitonin Gene-
Related Peptide (CGRP), a mediator of itch, sensory nerve
hypersensitisation and neurogenic inflammation, in dorsal
root ganglion (DRG) isolated from adult rats and stimulated
with NGF
● BEN-2293 demonstrates excellent tolerability and safety
margins in IND/CTA-enabling toxicology studies
Key: Tropomyosin-related kinase (Trk) receptor tyrosine kinase family, namely TrkA, TrkB, and
TrkC; Nerve Growth Factor (NGF); Brain Derived Neurotrophic Factor (BDNF); Neurotrophin-3
(NTF-3)/NT3
BEN-2293 Inhibition of human primary T-cell activation
Luminescence
% inhibition
25000
20000-
15000-
10000-
5000-
0.1
125-
100-
75-
50-
25-
0-
-25-
-50-
TNFa
TIE
10 100 1000 10000
BEN-2293 nM
-2
BEN-2293 mediated inhibition of CGRP in
DRG neurons (n=2)
- Donor 1
Donor 2
Hillslope 2.827
IC50
-1
Log BEN-2293 (UM)
0
0.03033
Human peripheral blood mononuclear cells from 2 blood donors.
Stimulated with a T-cell stimulus (anti-CD3/CD28) +/- BEN-2293
1
1500-
Luminescence
1000-
20
500-
04
IL-4
0.1
THE THIE
10
100 1000 10000
BEN-2293 nM
-Donor 1
- Donor 2
Inhibition of sensory
neuron activation
Benevolent
11View entire presentation